On September 10, 2026, IceCure Medical Ltd. announced it received approval from China’s National Medical Products Administration (NMPA) to market its ProSense® system and associated cryoprobes as a Class III medical device in China. This regulatory milestone enables the commercialization of the company's flagship cryoablation technology in the Chinese market, expanding its global reach beyond existing approvals in the U.S., Europe, and Asia. IceCure Medical Ltd. develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors by freezing.
